Subscribe

Carisma Therapeutics, Inc. (CARM)

USD0.01 +0.00 (+9.62%)
US OTC Healthcare Biotechnology
Address 3675 Market Street 19104
Philadelphia, PA, US
CEO Craig R. Jalbert
Website carismatx.com
IPO 2014-02-06
CIK 1485003 ISIN US14216R1014

Explore sections of this company profile

Description

Carisma Therapeutics, Inc., a biotechnology company, focuses on developing transformative therapies to treat liver fibrosis and cancer in the United States. Its product candidates include CT-2401, which is in preclinical trial for the treatment of liver fibrosis. The company also develops CT-1119, a mesothelin-targeted CAR-Monocyte that is in phase I clinical trial to treat patients with advanced mesothelin-positive solid tumors, including pancreatic cancer, ovarian cancer, lung cancer, mesothelioma, and others. In addition, it develops in vivo CAR-M cell therapy to treat solid tumors, including hepatocellular carcinoma. Carisma Therapeutics, Inc. has collaboration and license agreement with ModernaTX, Inc. to address oncology gene therapies. The company was formerly known as CARMA Therapeutics Inc. and changed its name to Carisma Therapeutics, Inc. in May 2017. Carisma Therapeutics, Inc. was founded in 2016 and is headquartered in Philadelphia, Pennsylvania.

Market Cap & Enterprise Value
Merger & Acquisition History

No mergers or acquisitions recorded for this company.

Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary Loading…
Indicator 1D1W2W3W1M
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
Averages
Trend
Price
Levels
Draw
USD0.01 +0.00 (+9.62%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
50.6K
Beta
0.80
Float Shares
30.14M
Free Float %
72.0%
Price Performance
1D5D1M3M6M YTD1Y3Y5Y10YMax
-60.00% -50.00% -99.42% -99.49% -99.56% -99.53% -99.90% -100.00% -100.00% -100.00% -100.00%
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
vs.
Loading histogram data…

Revenue flow

Revenue by geography

Revenue by segment

From To

Revenue composition

From To

By product

By geography

Financial Statements

Income Statement

Balance Sheet

Cash Flow Statement

Key Metrics

Financial Ratios

Employees

Financial Growth (CAGR)

Market Data

Analyst Consensus (6 ratings, all time) Hold
Price Targets & DCF
Current price
0.01
Low 6.00 +105,163.2%
Consensus 6.00 +105,163.2%
Median 6.00 +105,163.2%
High 6.00 +105,163.2%
Ratings Trend (MoM) 0% Bullish
Rating 2026-02 Change
Strong Buy 0 0
Buy 0 0
Hold 1 0
Sell 0 0
Strong Sell 0 0
Price Target Summary
Period # Analysts Avg Target
Last Month — —
Last Quarter — —
Last Year — —
All Time 1
6.00
+105,163.2%
Quality scores
Altman Z-Score
-45.90
Distress
Piotroski F-Score
3 / 9
Average
MOAT Score
1 / 10
No MOAT
Composite Rating
B
Overall Score
3 / 5
Medium
DCF Score
5 / 5
High
ROE Score
1 / 5
Low
ROA Score
5 / 5
High
D/E Score
1 / 5
Low
P/E Score
3 / 5
Medium
P/Book Score
1 / 5
Low
Operational MOAT
✗ Below peers
  • ✓
    Revenue growth Biotechnology: +1.6%
    +31.6% ★ Q3'25: +1,236.8% (vs Q3'24)
  • ✗
    EPS growth Biotechnology: +29.7%
    +43.6% ★ Q3'25: +445.2% (vs Q3'24)
  • ✗
    FCF margin FCF growth · Biotechnology: +16.2%
    -351.0% Q3'25: +4.2% (vs Q3'24)
  • ✗
    EBIT margin Biotechnology: +0.0%
    -306.5% Q3'25: +98.8% (vs Q3'24)
  • ✓
    ROIC Biotechnology: -16.1%
    — Q3'25: -6,206.4% (vs Q3'24)
  • ✗
    Share dilution Biotechnology: -3.4%
    +23.7% Q3'25: +1.0% (vs Q3'24)
  • ✗
    Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×
    -0.04× Q3'25: 0.00× (vs Q3'24)
Valuation Multiples From To
Price Forecast (3Y) From To
Model
Adjust
P/E
Theoretical Return — If Invested Today

* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.

DCF Interactive Model (UFCF)
Projection years:
Market assumptions
▶ WACC components (optional)
Ke (Cost of Equity) = Rf + β (1.31) × ERP
WACC = 0% × Ke + 100% × Kd (4.1%) × (1−t)

Modifying these values recalculates WACC automatically.

Business assumptions
—
Current price: 0.01
Enterprise Value: — Equity Value: — Terminal Value: — TV as % of EV: —

Base values reflect the latest available data for this company and market conditions.

Consensus Estimates
Metric Dec 2015
actual 		Dec 2017
actual 		Dec 2020
actual 		Dec 2021
actual 		Dec 2022
actual 		Dec 2023
actual 		Dec 2024
actual 		Dec 2025
actual 		Dec 2026
1 Rev. Ana.
1 EPS Ana. 		Dec 2027
1 Rev. Ana.
1 EPS Ana. 		Dec 2028
1 Rev. Ana.
1 EPS Ana. 		Dec 2029
1 Rev. Ana.
1 EPS Ana.
Revenue
990.0K
est: 500.0K (+98.0%)
425.0K
est: 425.0K (+0.0%)
11.24M
est: 11.22M (+0.1%)
26.54M
est: 6.51M (+307.4%)
9.83M
est: 40.00M (-75.4%)
14.92M
est: 15.07M (-1.0%)
19.63M
est: 21.09M (-6.9%)
15.00M
est.
9.11M
9.11M – 9.11M
-39.2% YoY
43.22M
43.22M – 43.22M
+374.2% YoY
9.98M
9.98M – 9.98M
-76.9% YoY
73.14M
73.14M – 73.14M
+632.5% YoY
EBITDA
-31.69M
est: -432.1K (-7,234.0%)
-28.74M
est: -367.3K (-7,725.9%)
-27.93M
est: -9.70M (-187.9%)
-8.52M
est: -5.63M (-51.4%)
-56.19M
est: -34.57M (-62.5%)
-85.89M
est: -13.03M (-559.4%)
-56.83M
est: -18.22M (-211.8%)
-12.96M
est.
-7.88M
-7.88M – -7.88M
+39.2% YoY
-37.35M
-37.35M – -37.35M
-374.2% YoY
-8.63M
-8.63M – -8.63M
+76.9% YoY
-63.21M
-63.21M – -63.21M
-632.5% YoY
EBIT
-32.06M
est: -432.4K (-7,313.2%)
-29.03M
est: -367.6K (-7,797.6%)
-28.38M
est: -9.71M (-192.3%)
-8.61M
est: -5.63M (-52.8%)
-58.08M
est: -34.59M (-67.9%)
-88.73M
est: -13.04M (-580.7%)
-60.18M
est: -18.24M (-230.0%)
-12.97M
est.
-7.88M
-7.88M – -7.88M
+39.2% YoY
-37.38M
-37.38M – -37.38M
-374.2% YoY
-8.63M
-8.63M – -8.63M
+76.9% YoY
-63.25M
-63.25M – -63.25M
-632.5% YoY
Net Income
-33.45M
est: -1.25B (+97.3%)
-29.03M
est: -878.87M (+96.7%)
-28.35M
est: -160.30M (+82.3%)
-336.0K
est: -58.04M (+99.4%)
-61.23M
est: -157.53M (+61.1%)
-86.88M
est: -83.00M (-4.7%)
-60.48M
est: -55.83M (-8.3%)
-29.04M
est.
-21.70M
-21.70M – -21.70M
+25.3% YoY
-18.12M
-18.12M – -18.12M
+16.5% YoY
-17.43M
-17.43M – -17.43M
+3.8% YoY
-17.41M
-17.41M – -17.41M
+0.1% YoY
SGA
9.85M
est: 551.8K (+1,684.9%)
7.90M
est: 469.1K (+1,584.2%)
5.09M
est: 12.39M (-58.9%)
29.39M
est: 7.19M (+308.8%)
9.38M
est: 44.15M (-78.8%)
29.53M
est: 16.64M (+77.5%)
20.14M
est: 23.27M (-13.5%)
16.56M
est.
10.06M
10.06M – 10.06M
-39.2% YoY
47.70M
47.70M – 47.70M
+374.2% YoY
11.02M
11.02M – 11.02M
-76.9% YoY
80.72M
80.72M – 80.72M
+632.5% YoY
EPS
-35.23
est: -30.27 (-16.4%)
-22.24
est: -21.20 (-4.9%)
-3.81
est: -3.87 (+1.5%)
-0.04
est: -1.40 (+97.4%)
-1.52
est: -3.80 (+60.0%)
-2.59
est: -2.00 (-29.4%)
-1.46
est: -1.35 (-8.4%)
-0.69
est.
-0.52
-0.52 – -0.52
+24.7% YoY
-0.44
-0.44 – -0.44
+16.5% YoY
-0.42
-0.42 – -0.42
+3.8% YoY
-0.42
-0.42 – -0.42
+0.1% YoY
Historical Ratings (3M)
Date Rating Overall DCF ROE ROA D/E P/E P/B
2026-05-11 B 3/5 5/5 1/5 5/5 1/5 3/5 1/5
2026-05-08 B 3/5 5/5 1/5 5/5 1/5 4/5 1/5
2026-05-07 B 3/5 5/5 1/5 5/5 1/5 4/5 1/5
2026-05-06 B 3/5 5/5 1/5 5/5 1/5 4/5 1/5
2026-05-05 B 3/5 5/5 1/5 5/5 1/5 4/5 1/5
2026-05-04 B 3/5 5/5 1/5 5/5 1/5 4/5 1/5
2026-05-01 B 3/5 5/5 1/5 5/5 1/5 4/5 1/5
2026-04-30 B 3/5 5/5 1/5 5/5 1/5 4/5 1/5
2026-04-29 B 3/5 5/5 1/5 5/5 1/5 4/5 1/5
2026-04-28 B 3/5 5/5 1/5 5/5 1/5 4/5 1/5
2026-04-27 B 3/5 5/5 1/5 5/5 1/5 4/5 1/5
2026-04-24 B 3/5 5/5 1/5 5/5 1/5 4/5 1/5
2026-04-23 B 3/5 5/5 1/5 5/5 1/5 4/5 1/5
2026-04-22 B 3/5 5/5 1/5 5/5 1/5 4/5 1/5
2026-04-21 B 3/5 5/5 1/5 5/5 1/5 3/5 1/5
2026-04-20 B 3/5 5/5 1/5 5/5 1/5 3/5 1/5
2026-04-17 B 3/5 5/5 1/5 5/5 1/5 3/5 1/5
2026-04-16 B 3/5 5/5 1/5 5/5 1/5 3/5 1/5

Owner Earnings

Owner's Earnings (history) From To
Owner alignment
Owner's Earnings TTM
-10.78M
OE per share TTM
-0.26
Owner's Yield
-128,993.54%
Maintenance CapEx ratio
33.66%
Maint CapEx / Avg PPE
35.9%

Ownership Overview

Ownership breakdown
At a glance
Institutional holders
7
Total invested
67.0K
Insider transactions (90d)
0
Beneficial owners (>5%)
1
Beneficial owners (>5%)
# Reporting person ⇅ Amount owned ⇅ % of class ⇅ Sole voting ⇅ Shared voting ⇅ Sole dispositive ⇅ Shared dispositive ⇅ Type Citizenship Filing date ⇅ SEC filing
1 AbbVie Biotechnology Ltd. 2.75M 6.80% — 2.75M — 2.75M OO Bermuda 2024-03-13 ↗

Institutional Activity (13F)

Institutional ownership trend From To
13F snapshot — 2025 Q4
Investors holding
7
-26 vs prev Q
New positions
2
Closed positions
28
Increased
3
Reduced
0
Put/Call ratio
0.00
Calls held
—
Puts held
—
Top institutional holders
# Investor ⇅ Shares / Δ ⇅ Mkt value / Δ ⇅ Own% / Δ ⇅ Weight% / Δ ⇅ Avg px / Perf. ⇅ Hold / Status ⇅
1 MERCK & CO., INC. 1.47M +— (+0.0%) 63.3K -340.3K (-84.3%) 3.53% +0.000 pp 0.02% -0.154 pp USD0.42 -90.5% 5 qtrs —
2 XTX TOPCO LTD 40.1K +40.1K (+100.0%) 1.7K +1.7K (+100.0%) 0.10% +0.096 pp 0.00% +0.000 pp USD0.04 +0.0% 1 qtrs NEW
3 EMPOWERED FUNDS, LLC 31.0K +— (+0.0%) 1.3K -7.2K (-84.3%) 0.07% +0.000 pp 0.00% 0.000 pp USD7.07 -99.4% 11 qtrs —
4 BAADER BANK AKTIENGESELLSCHAFT 19.5K +19.5K (+100.0%) 517.00 +517.0 (+100.0%) 0.05% +0.047 pp 0.00% +0.000 pp USD0.04 +0.0% 5 qtrs —
5 UNION BANCAIRE PRIVEE, UBP SA 785.00 +250.0 (+46.7%) 28.00 -103.0 (-78.6%) 0.00% +0.001 pp 0.00% +0.000 pp USD0.30 -86.7% 5 qtrs —
6 IFP ADVISORS, INC 206.00 +— (+0.0%) 9.00 -47.0 (-83.9%) 0.00% +0.000 pp 0.00% +0.000 pp USD3.10 -98.7% 12 qtrs —
7 ORG PARTNERS LLC 200.00 +— (+0.0%) 8.00 -46.0 (-85.2%) 0.00% +0.000 pp 0.00% +0.000 pp USD1.67 -97.6% 11 qtrs —
8 CAROLINA WEALTH ADVISORS, LLC — -150.0 (-100.0%) — -41.0 (-100.0%) 0.00% 0.000 pp 0.00% +0.000 pp USD— 5 qtrs SOLD
9 CITIGROUP INC — -11.3K (-100.0%) — -3.1K (-100.0%) 0.00% -0.027 pp 0.00% +0.000 pp USD— 2 qtrs SOLD
10 DYNAMIC FINANCIAL GROUP — -15.4K (-100.0%) — -4.2K (-100.0%) 0.00% -0.037 pp 0.00% -0.004 pp USD— 5 qtrs SOLD
11 BNP PARIBAS ARBITRAGE, SNC — -347.0 (-100.0%) — -95.0 (-100.0%) 0.00% -0.001 pp 0.00% +0.000 pp USD— 5 qtrs SOLD
12 GEODE CAPITAL MANAGEMENT, LLC — -250.5K (-100.0%) — -68.7K (-100.0%) 0.00% -0.599 pp 0.00% +0.000 pp USD— 12 qtrs SOLD
13 GOLDMAN SACHS GROUP INC — -16.4K (-100.0%) — -4.5K (-100.0%) 0.00% -0.039 pp 0.00% +0.000 pp USD— 11 qtrs SOLD
14 GROUP ONE TRADING, L.P. — -2.2K (-100.0%) — -611.0 (-100.0%) 0.00% -0.005 pp 0.00% +0.000 pp USD— 12 qtrs SOLD
15 GTS SECURITIES LLC — -50.1K (-100.0%) — -13.7K (-100.0%) 0.00% -0.120 pp 0.00% -0.001 pp USD— 3 qtrs SOLD
16 HARBOUR INVESTMENTS, INC. — -37.0 (-100.0%) — -10.0 (-100.0%) 0.00% 0.000 pp 0.00% +0.000 pp USD— 7 qtrs SOLD
17 ADVISOR GROUP HOLDINGS, INC. — -142.0 (-100.0%) — -29.0 (-100.0%) 0.00% 0.000 pp 0.00% +0.000 pp USD— 12 qtrs SOLD
18 JONES FINANCIAL COMPANIES LLLP — -16.0 (-100.0%) — -5.0 (-100.0%) 0.00% +0.000 pp 0.00% +0.000 pp USD— 4 qtrs SOLD
19 JPMORGAN CHASE & CO — -921.0 (-100.0%) — -252.0 (-100.0%) 0.00% -0.002 pp 0.00% +0.000 pp USD— 12 qtrs SOLD
20 BLODGETT WEALTH ADVISORS, LLC — -24.0K (-100.0%) — -6.6K (-100.0%) 0.00% -0.057 pp 0.00% -0.005 pp USD— 12 qtrs SOLD
21 MORGAN STANLEY — -3.2K (-100.0%) — -873.0 (-100.0%) 0.00% -0.008 pp 0.00% +0.000 pp USD— 12 qtrs SOLD
22 NATIONAL BANK OF CANADA /FI/ — -50.0 (-100.0%) — -13.0 (-100.0%) 0.00% 0.000 pp 0.00% +0.000 pp USD— 12 qtrs SOLD
23 NORTHERN TRUST CORP — -55.0K (-100.0%) — -15.1K (-100.0%) 0.00% -0.132 pp 0.00% +0.000 pp USD— 12 qtrs SOLD
24 RENAISSANCE TECHNOLOGIES LLC — -293.7K (-100.0%) — -80.5K (-100.0%) 0.00% -0.703 pp 0.00% 0.000 pp USD— 12 qtrs SOLD
25 SBI SECURITIES CO., LTD. — -107.0 (-100.0%) — -29.0 (-100.0%) 0.00% 0.000 pp 0.00% +0.000 pp USD— 5 qtrs SOLD
26 STATE STREET CORP — -85.1K (-100.0%) — -23.3K (-100.0%) 0.00% -0.204 pp 0.00% +0.000 pp USD— 12 qtrs SOLD
27 TWO SIGMA SECURITIES, LLC — -12.8K (-100.0%) — -3.5K (-100.0%) 0.00% -0.031 pp 0.00% -0.001 pp USD— 5 qtrs SOLD
28 UBS GROUP AG — -7.0K (-100.0%) — -1.9K (-100.0%) 0.00% -0.017 pp 0.00% +0.000 pp USD— 12 qtrs SOLD
29 BLACKROCK, INC. — -336.8K (-100.0%) — -92.3K (-100.0%) 0.00% -0.806 pp 0.00% +0.000 pp USD— 6 qtrs SOLD
30 VANGUARD GROUP INC — -350.3K (-100.0%) — -96.0K (-100.0%) 0.00% -0.838 pp 0.00% +0.000 pp USD— 12 qtrs SOLD
31 VIRTU FINANCIAL LLC — -22.9K (-100.0%) — -6.0K (-100.0%) 0.00% -0.055 pp 0.00% 0.000 pp USD— 2 qtrs SOLD
32 BRIDGEWAY CAPITAL MANAGEMENT, LLC — -31.0K (-100.0%) — -8.5K (-100.0%) 0.00% -0.074 pp 0.00% 0.000 pp USD— 12 qtrs SOLD
33 BANK OF AMERICA CORP /DE/ — -1.4K (-100.0%) — -383.0 (-100.0%) 0.00% -0.003 pp 0.00% +0.000 pp USD— 12 qtrs SOLD
Ownership breakdown by holder

ETF Ownership

Top ETFs holding this stock Held by 14 ETFs in our universe
# ETF Weight Est. AUM exposure TER
1 Schwab International Small-Cap Equity ETF SCHC 0.05% 2.56M 0.06%
2 Schwab Fundamental International Small Company Index ETF FNDC 0.04% 1.09M 0.39%
3 State Street SPDR Portfolio Europe ETF SPEU 0.01% 55.4K 0.07%
4 Vanguard Extended Market ETF VXF 0.00% 28.11 0.05%
5 Vanguard All-Equity ETF Portfolio VEQT.TO 0.00% — 0.22%
6 Vanguard Growth ETF Portfolio VGRO.TO 0.00% — 0.22%
7 Vanguard Total Stock Market ETF VTI 0.00% — 0.03%
8 Vanguard U.S. Total Market Index ETF (CAD-hedged) VUS.TO 0.00% — 0.17%
9 Vanguard U.S. Total Market Index ETF VUN.TO 0.00% — 0.17%
10 Vanguard U.S. Total Market Shares Index ETF VTS.AX 0.00% — 0.03%

Insider Activity

Insider Activity — Latest Quarter
Ratio by transactions
0.20
Bearish
Ratio by volume
0.10
Bearish
Buys
1
Sells
5
Shares acquired
57.0K
Shares disposed
598.3K
Cash buys
—
Cash sales
4.00
Net activity
-541,329
Insider buys vs sells (history) From To
Recent insider transactions From To
Date Person Role Transaction A/D Security Shares Price Value Owned after D/I Filing
2025-10-07 Klichinsky Michael Officer M-Exempt A Common Stock 56,982 0.11 6.3K 56,982 D ↗
2025-10-03 Klichinsky Michael Officer S-Sale D Common Stock 119,347 0.26 31.1K 0 D ↗
2025-10-02 Klichinsky Michael Officer S-Sale D Common Stock 200,000 0.25 50.9K 119,347 D ↗
2025-10-01 Klichinsky Michael Officer S-Sale D Common Stock 165,000 0.26 42.4K 319,347 D ↗
2025-01-28 Klichinsky Michael Officer A-Award A Stock Option (Right to Buy) 221,000 0.50 110.5K 221,000 D ↗
2025-01-28 Kelly Steven Director / Officer A-Award A Stock Option (Right to Buy) 500,000 0.50 250.0K 500,000 D ↗
2025-01-01 McAndrew Natalie Officer — — — 0 0.00 — 0 — ↗
2024-10-31 Cheng Sohanya Roshan Director A-Award A Stock Option (Right to Buy) 38,700 0.97 37.5K 38,700 D ↗
2024-07-01 Thorell Marella Director A-Award A Stock Option (Right to Buy) 38,700 1.67 64.6K 38,700 — ↗
2024-07-01 Scadden David Director A-Award A Stock Option (Right to Buy) 38,700 1.67 64.6K 38,700 — ↗
2024-06-30 Thorell Marella Director — — — 0 0.00 — 0 — ↗
2024-06-30 Scadden David Director — — — 0 0.00 — 0 — ↗
2024-06-26 ZWEIFACH SANFORD S Director A-Award A Stock Option (Right to Buy) 19,350 1.22 23.6K 19,350 — ↗
2024-06-26 Torok Michael Director A-Award A Stock Option (Right to Buy) 19,350 1.22 23.6K 19,350 — ↗
2024-06-26 Morrison Briggs Director A-Award A Stock Option (Right to Buy) 19,350 1.22 23.6K 19,350 — ↗
2024-06-26 Hohneker John Director A-Award A Stock Option (Right to Buy) 19,350 1.22 23.6K 19,350 — ↗
2024-06-17 Morris Richard Steven Officer A-Award A Stock Option (Right to Buy) 85,000 1.03 87.6K 85,000 — ↗
2024-06-17 Klichinsky Michael Officer A-Award A Stock Option (Right to Buy) 85,000 1.03 87.6K 85,000 — ↗
2024-06-17 Kelly Steven Director / Officer A-Award A Stock Option (Right to Buy) 125,000 1.03 128.8K 125,000 — ↗
2024-04-01 Hohneker John Director A-Award A Stock Option (Right to Buy) 38,700 2.09 80.9K 38,700 — ↗
2024-01-31 Morris Richard Steven Officer A-Award A Stock Option (Right to Buy) 170,500 2.10 358.1K 170,500 — ↗
2024-01-31 Klichinsky Michael Officer A-Award A Stock Option (Right to Buy) 170,500 2.10 358.1K 170,500 — ↗
2024-01-31 Kelly Steven Director / Officer A-Award A Stock Option (Right to Buy) 438,000 2.10 919.8K 438,000 — ↗

Executive team

Top executives
EBIT / Employee
-13.1K
Shares Outstanding
41.85M

Executive compensation

Executive compensation (annual)
# Year ⇅ Executive ⇅ Salary ⇅ Bonus Stock award ⇅ Option award Incentive Other Total ⇅ % Stock-
based ⇅		 Filing
1 2023 Steven Kelly Current President & Chief Executive Officer 460.8K 301.8K — 2.72M — 24.2K 3.50M 77.55% ↗
2 2023 Thomas R. Cannell, D.V.M. Former President and Chief Executive Officer 104.2K — — — — 3.03M 3.13M 0.00% ↗
3 2023 Richard Morris Current Chief Financial Officer 384.3K 183.1K — 1.08M — 17.5K 1.66M 64.83% ↗
4 2023 Michael Klichinsky, Pharm.D., Ph.D. Current Chief Scientific Officer 345.6K 164.6K — 1.08M — 15.2K 1.60M 67.23% ↗
5 2023 Monica Forbes Former Chief Financial Officer and Treasurer 72.3K — — — — 1.28M 1.35M 0.00% ↗
6 2023 Mark Sullivan Former General Counsel, Chief Compliance Officer and Corporate Secretary 69.1K — — — — 1.05M 1.12M 0.00% ↗
7 2022 Thomas R. Cannell, D.V.M. Former President and Chief Executive Officer 576.6K — 813.7K — — 4.0K 1.39M 58.36% ↗
8 2022 Monica Forbes Former Chief Financial Officer and Treasurer 399.8K — 484.8K — — 4.0K 888.6K 54.56% ↗
9 2022 Mark Sullivan Former General Counsel, Chief Compliance Officer and Corporate Secretary 382.0K — 303.5K — — 4.0K 689.6K 44.02% ↗
CEO compensation breakdown

Proxy statements

Proxy statements (DEF 14A)
Filing date Form type Filing
2025-07-31 DEFA14A ↗
2025-07-07 DEF 14A ↗
2025-06-27 PRE 14A ↗
2024-04-29 DEF 14A ↗

Recent SEC filings

Recent SEC filings
Filing date Form type Filing
2025-12-29 15-12G ↗
2025-12-16 EFFECT ↗
2025-12-16 EFFECT ↗
2025-12-16 EFFECT ↗
2025-12-16 EFFECT ↗
2025-12-15 S-8 POS ↗
2025-12-15 S-8 POS ↗
2025-12-15 S-8 POS ↗
2025-12-15 S-8 POS ↗
2025-12-15 S-8 POS ↗

Executive team

NameTitleCompensationGender
Natalie McAndrew Vice President of Finance — female
Saar Gill Co-Founder & Chairman of Scientific Advisory Board — male
ESG Rating
B
BIOTECHNOLOGY
2025
E (Environmental)
76.0 / 56.3
Company / Sector avg.
S (Social)
66.5 / 62.4
Company / Sector avg.
G (Governance)
73.5 / 60.9
Company / Sector avg.
ESG Total
72.0 / 59.9
Company / Sector avg.
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Senate Trading Activity

No Senate trading activity found for this company.

House Trading Activity

No House trading activity found for this company.

Market share among peers
Peer comparison — filtered group (TTM)
Your opinion

Share your view on this stock and instantly see how the community has voted over the last 6 months.

These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.

Dividend history

Earnings history

Earnings reports

Stock splits

Related companies

Largest companies in Biotechnology